Trinity Biotech (TRIB) Long-Term Debt Issuances (2020 - 2024)

Trinity Biotech has disclosed Long-Term Debt Issuances across 5 years of filings, most recently posting $6.5 million for Q2 2024.

• In Q2 2024, Long-Term Debt Issuances rose 4321.09% year-over-year to $6.5 million; the TTM figure through Jun 2024 stood at $33.2 million (up 555.24% YoY), while the FY2025 annual figure was $15.0 million, down 50.29% from the prior year.
• Long-Term Debt Issuances came in at $6.5 million for Q2 2024 at Trinity Biotech, down from $21.7 million in the prior quarter.
• In the past five years, Long-Term Debt Issuances ranged from a high of $80.0 million in Q1 2022 to a low of -$60.0 million in Q2 2022.
• Average Long-Term Debt Issuances over 5 years is $4.8 million, with a median of $1.8 million recorded in 2021.
• Year-over-year, Long-Term Debt Issuances jumped 4436.0% in 2022 and slumped 93.93% in 2023.
• Over 5 years, Long-Term Debt Issuances stood at -$4.5 million in 2020, then soared by 60.97% to -$1.8 million in 2021, then soared by 103.57% to $63000.0 in 2022, then jumped by 133.33% to $147000.0 in 2023, then jumped by 4321.09% to $6.5 million in 2024.
• Per Business Quant data, the three most recent Long-Term Debt Issuances figures were $6.5 million in Q2 2024, $21.7 million in Q1 2024, and $147000.0 in Q2 2023.